Technology ID

Pyrophosphate Analog HIV-1 Reverse Transcriptase Inhibitors

Linked ID
David Shock (NIEHS)
Samuel Wilson (NIEHS)
William (Bill) Beard (NIEHS)
Lead Inventors
Samuel Wilson (NIEHS)
David Shock (NIEHS)
William (Bill) Beard (NIEHS)
Development Stages
Pre-Clinical (in vitro)
Commercial Applications
  • Anti-microbial
  • HIV therapeutic
The invention relates to compounds that inhibit HIV-1 DNA synthesis mediated by reverse transcriptase (RT). HIV-1 DNA synthesis by RT utilizes deoxynucleoside 5’-triphosphate (dNTP) as substrate and like many other enzymes, the reaction is reversible. Pyrophosphate analogs like imidodiphosphate strongly promote reverse reaction dNTP products containing the imidodiphosphate group instead of the naturally occurring pyrophosphate group. This imidodiphosphate-containing dNTP was found to be a potent inhibitor of the forward RT reaction. Whereas pyrophosphorolysis is limited by a nonchemical step, replacing the bridging oxygen of pyrophosphate with an imido group resulted in a change in the rate-limiting step, so that the imidodiphosphate-dependent reverse reaction was limited by chemistry. There exists, then, the potential to use pyrophosphate analogs therapeutically.

Request More Info

Licensing Contact